Iconic Therapeutics snags $20 mln

Iconic Therapeutics said Wednesday that it has closed $20 million in Series B-1 financing. The investors were MPM Capital, Lundbeckfond Ventures and H.I.G. BioVentures. In conjunction with the funding, Iconic has named MPM partner Dr. William Greene as CEO. Also, MPM’s Todd Foley, H.I.G’s Dr. Bruce Robertson and Dr. Johan Kordel of Lundbeckfond Ventures have been added to Iconic’s board of directors. Based in South San Francisco and Atlanta, Iconic is a biotech firm focused on serious eye disorders.

VC-backed Syndax Pharmaceuticals files for IPO

Syndax Pharmaceuticals has filed for an IPO. The number of shares that will be offered as well as the stock’s pricing terms have yet to be set. Deutsche Bank Securities and Jefferies are serving as lead underwriters. Headquartered in Waltham, Mass., Syndax is a Syndax Pharmaceuticals is a developer of epigenetic therapies for treatment-resistant cancers. Its backers include Domain Associates, MPM Capital, Forward Ventures, Pappas Ventures and Avalon Ventures.


VC-backed TriVascular files for IPO

TriVascular Technologies has filed for an IPO. The number of shares that will be offered as well as its pricing terms have yet to be set. The stock will trade on the NASDAQ under the ticker symbol “TRIV.” J.P. Morgan Securities and Credit Suisse Securities are the lead underwriters. Based in Santa Rosa, Calif., TriVascular Technologies is a provider of endovascular aortic repair solutions. Its backers include NEA, Delphi Ventures, MPM Capital, Kearny Venture Partners, Kaiser Permanente Ventures, Rock Springs Capital and Permal Asset Management.

MPM Capital Takes Minority Stake in InformedDNA

MPM Capital has acquired a minority stake in InformedDNA, a US provider of genetic counseling and genetic benefits management services. The investment fr­om MPM’s SunStates Fund will be used to expand InformedDNA’s current genetic benefits utilization management offerings while also funding the development of new specialty genetic services for the pharmaceutical industry.

Epizyme Files for an IPO

Epizyme, a six-year-old, Cambridge, Mass.-based biopharmaceutical company that’s focused on researching treatments for tumors and blood cancer, has filed an S-1 with the SEC.

23andMe Raises More Than $50M From Milner, NEA, Brin, Google, Others

23andMe, Inc. said it raised more than $50 million in a Series D financing with new investor Yuri Milner joined by existing investors Google co-founder Sergey Brin, 23andMe CEO Anne Wojcicki, New Enterprise Associates, Google Ventures and MPM Capital. The company said the Series D investment, along with rapidly decreasing costs, allowed it to lower the price of its Personal Genome Service to $99,

Selexys Pharmaceuticals Completes Series A Led by MPM Capital

Selexys Pharmaceuticals has completed a $23 million Series A equity financing, led by MPM Capital. Selexys has also entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, following the successful completion of a Phase 2 clinical study in patients with sickle cell disease. Including upfront, acquisition and milestone payments, the agreement with Novartis could reach up to $665 million.

Astute Medical Wraps Up Big Biomarker Round

Astute Medical, the San Diego-based biomarker-based medical diagnostics firm, took in more than $40 million in a big Series C round, the company revealed. The financing was led by MPM Capital, and included new investor Kaiser Permanente Ventures. Prior backers De Novo Ventures, Delphi Ventures, Domain Associates and Johnson & Johnson Development Corporation also joined […]

Aratana Therapeutics Inks $15M

Aratana Therapeutics, a company developing medicines for companion animals, has closed on $15 million in Series B financing. The company, since its launch earlier this year, has raised a total of $31 million. Existing shareholders MPM Capital, Avalon Ventures and Cultivian Ventures contributed to the round, as did new investor the Ewing Marion Kauffman Foundation. The company is based in Kansas City, Kansas.

Young Verastem Files for an IPO

Verastem, a Cambridge, Mass.-based biopharmaceutical company focused on developing cancer-fighting drugs, has filed a registration statement with the SEC to go public. The number of shares and price range have not yet been determined. The 15-month-old company has raised $48 million in venture financing since its founding, including from Advanced Technology Ventures, MPM Capital, Bessemer […]

PEHUB Community

Join the 12493 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget